Autonomix Medical (NASDAQ:AMIX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Autonomix Medical (NASDAQ:AMIX – Free Report) from a sell rating to a hold rating in a research report sent to investors on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Autonomix Medical in a research report on Monday, October 26th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Autonomix Medical presently has a consensus rating of “Hold” and an average price target of $42.00.

Check Out Our Latest Report on AMIX

Autonomix Medical Price Performance

Shares of Autonomix Medical stock opened at $1.10 on Friday. The stock has a 50 day moving average of $2.99 and a 200 day moving average of $6.36. Autonomix Medical has a 12 month low of $0.93 and a 12 month high of $32.55.

Autonomix Medical (NASDAQ:AMIX – Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($2.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.62) by $0.11. As a group, analysts forecast that Autonomix Medical will post -20.17 earnings per share for the current fiscal year.

Autonomix Medical Company Profile

(Get Free Report)

Autonomix Medical is a development-stage medical technology company focused on catheter-based tools for detecting and treating conditions involving the nervous system. Its platform combines miniature sensors with catheter technology to identify nerve signals and help guide targeted treatment. The company is developing the technology for potential use in pain management and other applications, including conditions involving the cardiovascular system. Its initial focus includes addressing pain associated with pancreatic cancer.

Further Reading

Receive News & Ratings for Autonomix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autonomix Medical and related companies with MarketBeat.com's FREE daily email newsletter.